HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017

ER+/HER2+ Metastatic Breast Cancer

October 2nd 2017

Future Directions: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

Treatment Selection for HR+ mBC

October 2nd 2017

mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

October 2nd 2017

CDK4/6 Inhibitors in Breast Cancer: Ongoing Research

October 2nd 2017

FDA Approval for Abemaciclib

October 2nd 2017

MONARCH 3: Abemaciclib With Endocrine Therapy for mBC

October 2nd 2017

MONARCH 1: Abemaciclib Monotherapy for HR+ mBC

October 2nd 2017

Abemaciclib + Fulvestrant at Progression of HR+ mBC

October 2nd 2017

Abemaciclib for ER+ mBC

October 2nd 2017

CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC

October 2nd 2017

Clinical Experience: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

CDK 4/6 Inhibitors in Metastatic Breast Cancer

October 2nd 2017

FDA Grants Pertuzumab Priority Review for HER2+ Early Breast Cancer

September 29th 2017

The FDA has granted a priority review to a supplemental biologics license application for pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

Cleveland Clinic Researcher Recaps Successes and Stumbles in Dual HER2 Targeting

September 25th 2017

Although dual HER2 blockade strategies have become an important part of the treatment paradigm for patients with HER2-positive breast cancer, the complexities of administering these therapies continue to unfold.

Stage, ER Status Guide HER2 Therapy Selection in Breast Cancer

September 17th 2017

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

September 8th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

September 7th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Finding the Right Place for Dual HER2 Blockade in Breast Cancer and Beyond

September 4th 2017

Although drugs that target HER2 have transformed the prognosis for many patients with breast cancer, the development of resistant disease remains a significant clinical challenge.

x